Condition 1: male infertility. Condition 2: Female infertility. Male infertility Female infertility, unspecified
Conditions
Interventions
Treatment - Drugs
group 1: highly purified-human HMG starting with the dose of 225 IU/day
group 2: human-FSH starting with the dose of 225 IU/day
group 3: recombinant-FSH starting with the dose of 225 IU/day
group 4: human-FSH for 6 days followed by recombinant-FSH starting with 225 IU/day
Intervention 1: group 1: highly purified-human HMG starting with the dose of 225 IU/day. Intervention 2: group 2: human-FSH starting with the dose of 225 IU/day. Intervention 3: group 3: recombinant-F
Sponsors
Shiraz university of Medical Sciences, Infertility research center
Eligibility
Sex/Gender
Female
Age
20 Years to 38 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Infertility with male factor or with unexplained cause. Exclusion criteria: all the cases with known female factor.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of oocytes. Timepoint: At the time of Harvesting the oocytes. Method of measurement: Counting the oocytes.;Quality of oocytes. Timepoint: At the time of oocyte retrival. Method of measurement: based on quality grading(GV-MI-MII).;Embryo count. Timepoint: 3 days after oocyte retrival. Method of measurement: microscopic evaluation.;Evaluation of expression of HAS2 Gene. Timepoint: after oocyte retrival. Method of measurement: Polymerase Chain Reaction (PCR).;Quantity of GREM1 expression. Timepoint: at the time of oocyte retrival. Method of measurement: PCR test.;Evaluation of expression of PGS2 Gene. Timepoint: after oocyte retrival. Method of measurement: Polymerase Chain Reaction (PCR). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Bahia Namavar Jahromi
Shiraz university of Medical Sciences, Infertility research center
Outcome results
None listed